Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of allo-SCT for R/R CD22+ Lymphoid Malignancies"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Issa Khouri
By
Insights from 2023 ASH Annual Meeting
FEATURING
Issa Khouri
Login to view comments.
Click here to Login